(VCBeat) Aug. 06, 2021 -- Belle Healthcare Technology Co., Ltd. ("Belle Healthcare"), a leading micro instrument manufacturer in China, recently announced the completion of a Series B financing of 100 million yuan, led by Sinovation Ventures, with participation from Jiuyou Fund and SND Ventures Group. The existing investors Dan Capital continued to invest in the latest round. Gelu Capital acted as the exclusive financial advisor. The funds raised will be used for R&D, registration, production line construction, marketing and operational support.

Belle Healthcare provides the highest quality micro-instruments for ophthalmic community. Original founded in 2009 named Belle in Focus as an OEM manufacturer for customers in Europe and USA (North America). The company was reorganized, and its name was changed in 2017 to expand its profile to disposable instruments, ENT instruments and consumable products. In China, Belle Healthcare is recognized as a full-service brand due to its customized designing capability, advanced R&D equipment, direct salesforce and after-sale service. For the international market, Belle Healthcare has established distribution channels for customers in Europe and Southeast Asia. 

Belle Healthcare's product line covers anterior segment surgery (for treatment of cataract, glaucoma, femtosecond, excision, ICL, etc.), posterior segment surgery (vitreoretinal surgery), full range of otology surgical package (lateral skull base surgery, otitis media, artificial ossicular implant, cochlear implant). Its core founding team used to be the only OEM partner of the global micro instrument leading brand in China, with many years of experience working for the world-famous brands and has the ability to expand the international market and provide ODM services.

Sinovation Ventures is a leading Chinese technology venture capital, started in 2009 by a team led by Dr. Kai-Fu Lee, with presences in Beijing, Shanghai, Nanjing, Guangzhou, and Shenzhen. It currently manages over $2B AUM between seven USD and RMB funds in total, and over 350 portfolio companies across the technology spectrum in China. The company invests in start-ups at the seed, Series A and Series B stages.

since its establishment in November 2011， Jiuyou Fund has been an innovative platform with three distinctive functions, e.g., investment fund, technology promotion in new cities, and industry research institute.

Jiuyou Fund diversifies its investment portfolio, focuses on strategic and consumer industries, introduces viable projects with core IP rights and proven business models from North America, Europe and Japan.